peptides for muscle growth

recombinant hGH is the most-documented muscle effect in the human literature. tesamorelin is the only approval-grade peptide alternative. everything below them is community-grade or research-only.

the muscle-and-performance peptide conversation has a real top of stack. recombinant hGH (somatropin, FDA 1985, 11 brand names) holds the documented anabolic record in humans. tesamorelin (Egrifta, FDA november 2010) is the only approval-grade peptide GH-axis secretagogue and the legal endocrinology-clinic alternative for body composition.

two flavors get searched below that line. gh-axis stimulators (cjc-1295, ipamorelin, sermorelin) nudge the pituitary toward larger endogenous gh pulses. direct-intervention compounds (igf-1 lr3, follistatin-344) bypass that regulation entirely. the october 2024 PCAC vote pulled ipamorelin and CJC-1295 out of routine 503A compounding. igf-1 lr3 and follistatin-344 land in F-tier because the chronic-use safety record is empty, not because the muscle signal is implausible.

recombinant hGH leads, tesamorelin is the approval-grade peptide alternative.

the actual hormone, then the peptide secretagogue with phase-3 trial data. these are the FDA-approved options for body composition.

hgh (somatropin) (tier S) — recombinant human growth hormone. genentech Protropin 1985. 11 brand names across daily and weekly cadences by 2026.
tesamorelin (tier S) — GHRH analog. FDA-approved november 2010 as Egrifta SV for HIV-associated visceral lipodystrophy.
cjc-1295 + ipamorelin blend (tier A) — GHRH analog plus selective GHRP. the community-standard GH-axis stack.

what else gets searched, and where the data is.

compounds frequently searched alongside the gh-axis class. zero FDA approvals for any indication. some carry documented safety considerations the marketing rarely mentions.

cjc-1295 (tier A) — GHRH analog with maleimidopropionic albumin handle (DAC). 6-8 day half-life.
ipamorelin (tier A) — selective ghrelin-receptor agonist. raun et al. 1998 swine model: GH release at 200x effective dose with no cortisol, prolactin, FSH, LH, TSH, or ACTH movement.
sermorelin (tier A) — GHRH(1-29). EMD Serono Geref, FDA-approved 1990 as a diagnostic and 1997 for pediatric GHD. commercially discontinued dec 2 2008.
hgh frag 176-191 (tier C) — c-terminal residues 176-191 of hgh. ng and wallis monash 1990s, roughly 3-fold glycerol release in obese mice.
ghrp-2 (tier D) — first-generation gh-releasing peptide. documented cortisol and prolactin elevation.
ghrp-6 (tier D) — older ghrp. defining feature is appetite stimulation via the ghrelin receptor.
igf-1 lr3 (tier F) — long-acting igf-1 analog. half-life ~20-30 hours.
follistatin 344 (tier F) — myostatin antagonist that broadly inhibits multiple tgf-β family proteins.

specific-question reference.

is any peptide fda-approved for muscle growth in healthy adults?

no. tesamorelin is approved for hiv-associated visceral lipodystrophy. sermorelin was approved 1997 for pediatric ghd and discontinued commercially dec 2 2008. somatropin (hgh) is approved for documented gh deficiency and a handful of other endocrine indications. nothing on this page carries a muscle-growth indication in healthy adults. that is a gap in the regulatory record.

why are igf-1 lr3 and follistatin-344 in F-tier when the muscle signal is plausible?

tier reflects the published safety record, not the strength of the hypertrophy signal. igf-1 elevation is a documented epidemiologic cancer-promotion factor and lr3 produces supraphysiological exposure. follistatin-344 has zero published human trials and broadly inhibits the tgf-β family that includes tumor-suppressor signals. the muscle effect can be real and the safety dataset can still be empty. both are true.

what does the gh-axis trial data actually show on body composition?

modest single-digit-percent shifts in healthy adults. real but smaller than marketing language implies. tesamorelin has the deepest fda-monitored dataset (lipo trials, n>800, 15-18% visceral adipose reduction inside the hiv indication). cjc-1295 has one peer-reviewed human pk trial. ipamorelin has the raun 1998 swine selectivity paper plus a decade of clinic use. none of this is a muscle-hypertrophy phase 3.

what does the literature show on combining peptides with weight-loss compounds?

no published peptide-on-peptide combination trials. SURMOUNT and STEP ran resistance-training subgroups but did not test secretagogue stacks alongside glp-1 therapy. the evidence gap is the relevant fact.

what's in the data for older adults concerned about age-related lean-mass loss?

sermorelin has the longest fda-approval history but the approval is pediatric ghd, not adult sarcopenia. gh-axis research in older adults reports modest effects. resistance training and adequate protein remain the primary published interventions.

do peptide trials show muscle growth without resistance training?

no. published research consistently identifies the training stimulus as the primary driver of muscle protein synthesis. peptide effects in the literature modulate training-driven responses. claims to the contrary are marketing.

what the safety literature reports.

what side effects are documented in the gh-axis literature?

water retention, peripheral edema, joint discomfort, transient hand paresthesias, sleep alterations. all dose-dependent. tachyphylaxis (effect-fade) is described on continuous gh-axis stimulation.

is there a cancer-risk concern with gh-axis stimulation?

elevated igf-1 is a documented cancer-promotion factor in epidemiology. gh-axis stimulation does raise igf-1. magnitudes from cjc-1295, ipamorelin, and sermorelin at clinical doses are smaller than direct igf-1 supplementation. specific cancer-incidence data in healthy adults researching these compounds outside approved indications has not been published. absence of data is not evidence of safety.

what does the long-term safety data show?

varies by compound. tesamorelin and sermorelin have the longest fda-monitored datasets inside their approved indications. cjc-1295 and ipamorelin have roughly ten years of community use but no formal long-term studies. igf-1 lr3 and follistatin-344 have effectively no characterized long-term human safety data. the mechanistic concerns are documented in the receptor biology.

what about insulin sensitivity?

gh-axis stimulation can reduce insulin sensitivity in published research. magnitudes vary across studies. the long-term healthy-adult risk record outside approved indications remains thin.

related comparisons

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.